CPX-351 in Down syndrome–associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial
Top Cited Papers
Open Access
- 15 January 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (3) , 229-240
Abstract
Myeloid leukemia of Down syndrome (ML-DS) is associated with an excellent prognosis but high treatment-related toxicity and mortality. The Phase 3 Clinical Trial for CPX-351 in ML-DS 2018 aimed to maintain the excellent event-free survival (EFS) achieved in the previous ML-DS 2006 trial while reducing the treatment intensity. Intensity-reduced induction and reinduction therapy with cytarabine and idarubicin with or without etoposide was replaced with CPX-351 (66 U/m2 on 3 days in course 1 and on 2 days in course 2). Risk stratification was based on flow cytometric measurable residual disease (MRD) after first induction. High-risk patients received high-dose cytarabine (3 g/m2 per 12 hour) in consolidation; standard-risk patients received cytarabine at a dose of 1 g/m2 per 12 hour. A total of 35 patients were enrolled until the trial was halted because of an unexpectedly high relapse rate. A per-protocol interim analysis revealed a significantly lower 24-month EFS when compared with the ML-DS 2006 trial (69% vs 90%; P< .001). In contrast with previous studies, most patients who relapsed responded to salvage therapy, leading to a comparable 24-month overall survival of 88% (vs 92%; P = .612). CPX-351 demonstrated a favorable toxicity profile with no treatment-related mortality. Positive MRD by error-corrected GATA1 next-generation sequencing, the presence of trisomy 8 or a complex karyotype were associated with an increased risk for relapse. In conclusion, replacing intensity-reduced induction therapy with CPX-351 in ML-DS led to a significantly lower EFS, highlighting the need for dose optimization to balance the efficacy and toxicity in this sensitive patient population. This trial was registered at https://www.clinicaltrialsregister.eu as EudraCT #2018-002988-25.Keywords
This publication has 39 references indexed in Scilit:
- Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndromePediatric Blood & Cancer, 2024
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialThe Lancet Haematology, 2021
- Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animalsNanomedicine: Nanotechnology, Biology and Medicine, 2020
- Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down SyndromeCancer Cell, 2019
- Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessmentCancer Chemotherapy and Pharmacology, 2017
- Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML‐BFM 2004Pediatric Blood & Cancer, 2016
- Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in JapanPediatric Blood & Cancer, 2015
- The landscape of somatic mutations in Down syndrome–related myeloid disordersNature Genetics, 2013
- Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down SyndromeTransplantation and Cellular Therapy, 2013
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacyLeukemia Research, 2009